Upload
astrid
View
46
Download
1
Embed Size (px)
DESCRIPTION
Health Work Programme 2011 - FP7 ( 5 th year call s ). Рабочая программа «Здоровье - 201 1-7 РП » ( 5-й конкурс ). Директорат «Здоровье» Генеральный директорат по науке Европейская комиссия. June 2009. - PowerPoint PPT Presentation
Citation preview
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
1
Директорат «Здоровье»Генеральный директорат по
наукеЕвропейская комиссия
June 2009
Health Work Programme 2011-FP7 (5th year calls)
Рабочая программа «Здоровье-2011-7РП » (5-й конкурс)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
2
HEALTH-NCP-NET – это сеть, объединяющая Национальные контактные точки (НКТ) по приоритетному направлению «Здоровье» в Европе и контактные точки за ее пределами.
Сайт Еврокомиссии по приоритетному направлению «Здоровье»:
http://cordis.europa.eu/fp7/health/home_en.html
Национальный информационный офис 7 РП ЕС в Беларуси: http://fp7-nip.org.by/Руководитель офиса:Мееровская Ольга Анатольевнател. +375 17 2867630e-mail:[email protected]
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
3
ГНУ «Институт биофизики и клеточной инженерии НАН Беларуси»
НАЦИОНАЛЬНАЯ КОНТАКТНАЯ ТОЧКА 7РП ЕС ПО ПРИОРИТЕТНОМУ НАПРАВЛЕНИЮ «ЗДОРОВЬЕ»
г. Минск, ул. Академическая, 27e-mail: [email protected]://ibp.org.by/ru/?page_id=229тел. + 375 17 284 15 68 + 375 17 284 23 57факс: + 375 17 284 23 59
Приказом Государственного комитета по науке и технологиям от 16 марта 2007 г. № 28 «О развитии научно-технического сотрудничества с Европейским Союзом» Институт биофизики и клеточной инженерии назначен Национальной контактной точкой (НКТ) 7РП ЕС по приоритетному направлению «Здоровье».
Основные направления деятельности:Распространение информации о возможностях участия белорусских ученых в проектах 7 Рамочной Программы.Консультирование действующих и потенциальных участников из Беларуси по вопросам подготовки заявок и реализации проектов.Поиск партнеров в странах ЕС для белорусских организаций, желающих присоединиться к формирующимся консорциумам, и наоборот – поиск партнеров в Беларуси по запросам организаций из ЕС.Реклама научно-технического потенциала Беларуси в странах ЕС для продвижения участия отечественных ученых в проектах 7 РП.Проведение информационных дней и семинаров.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
4
Типы программ7РП Европейского союза
• Cooperation (сотрудничество) –• Ideas (идеи) –• Реople (люди) - • Capacities (cпособности) – • Joint Research Projects (совместные
исслед. проекты) – • Euroatom (евроатом)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
5
Приоритеты научной и науч-но-технической деятельности
Европейского союза• 1.Energy (Энергетика )• 2.Environment (including Climate Change) (Окружающая среда,
включая изменения климата) • 3.Food, Agriculture and Fishery, Biotechnology (Питание, сельское
и рыбное хозяйство,биотехнологии) • 4.Нealth(Здоровье)• 5. Information and Communication Technologies (Информационные
и коммуникационные технологии) • 6. Nanosciences, Nanotechnologies, Materials and new Production
Technologies (Нанонауки, нанотехнологии, материалы и новые производственные технологии )
• 7. Socio-economic sciences and Humanities (Социально-экономические и гуманитарные науки)
• 8. Transport (including Aeronautics) (Транспорт, включая аэронавтику)
• 9. Security (Безопасность)
По приоритетам Еврокомиссия объявляет ежегодные конкурсы
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
6
Схемы финанси-рования
• Collaborative projects (совместные проекты);• Networks of excellence (сети превосходства)• Coordination and support actions (работы по
координации и поддержке)• Individual projects (индивидуальные
проекты)• Support for training and career
development of researches (поддержка совершенствования и карьерного роста исследователей)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
7
Совместные проекты
Выполняются консорциумами из пред-ставителей различных стран, проекты преследуют задачи: получение новых знаний, создание новых технологий и продукции, выполняются в рамках приоритетов по различным темам, предложено 3 типа совместных проектов (малые, средние и крупные), проекты могут быть ориентированы на специа-льные группы, например, SME.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
8
• Сети превосходства • Поддерживают совместные программы ряда
организаций (Joint Programme Activities), объединяющих свою деятельность в опре-деленной области исследований в ходе длительной кооперации
• Работы по координации и поддержке
• Поддерживают деятельность по координации и поддержке научных исследований (создание сетей, обмены учеными и информацией, транснациональный доступ к инфраструктурам и исследованиям, проведение конференций)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
9
• Индивидуальные проектыОсуществляются национальными или международными группами ученых по новым актуальным научным направле-ниям во взаимодействии с Европейским научно-исследовательским советом
• Поддержка совершенствования и карьерного роста ученых
Осуществляется через систему грантов им. Марии Кюри
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
10
Сети 7РП
В рамках схемы В рамках схемы Coordination and Support Coordination and Support Action Action Еврокомиссия создала ряд сетей:Еврокомиссия создала ряд сетей:
• IncoNet EECA IncoNet EECA http://www.inco-eeca.net• IncoNet CA/SC - S&T International Cooperation Network for IncoNet CA/SC - S&T International Cooperation Network for
Central Asian and South Caucasus Countries Central Asian and South Caucasus Countries http://icbss.org/index.php?option=com_content&task=view&id=273
• incrEAST - Information Exchange in Science and incrEAST - Information Exchange in Science and Technology between the European Research Area and Technology between the European Research Area and Eastern European / Central Asian Countries Eastern European / Central Asian Countries http://www.increast.eu/
• HEALTH-NCP-NET HEALTH-NCP-NET http://www.healthncpnet.eu/jahia/Jahia/ • INCONTACT network of the INCO-NCPs INCONTACT network of the INCO-NCPs
http://www.ncp-incontact.eu/nkswiki/index.php?titlehttp://www.ncp-incontact.eu/nkswiki/index.php?title==Main_PageMain_Page
• HITT-CIS - Health In Times Transition: HITT-CIS - Health In Times Transition: Trends in Population Health and Health Policies in CIS countries http://www.hitt-cis.net/
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
11
ERA-NETs:
• ERA.NET RUS Linking Russia to the ERA: Coordination of MS´/AC´ S&T programmes towards and with Russia http://www.era.net-rus.eu/, http://ec.europa.eu/research/iscp/pdf/russia_eranet.pdf
• BS-ERA.NET Networking on science and technology in the Black Sea region http://www.bs-era.net/main/index.php?we=9bfdbe988abcff430168e60524a69c11&wchk=c1960ad06e70dbaee80ab8641db51532, http://ec.europa.eu/research/iscp/pdf/black_sea.pdf
BILATs• BILAT-RUS Enhancing the bilateral S&T
Partnership with the Russian Federation http://www.bilat-rus.eu/, http://ec.europa.eu/research/iscp/pdf/russia_bilat.pdf
• BILAT-UKR Enhancing the bilateral S&T Partnership with Ukraine, http://www.bilat-ukr.eu/, http://ec.europa.eu/research/iscp/pdf/ukraine.pdf
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
12
Participation and Success Participation and Success RateRate in FP7 Health Researchin FP7 Health Research
• The countries of Eastern Europe and Central Asia The countries of Eastern Europe and Central Asia include: include: ArmeniaArmenia, Azerbaijan, , Azerbaijan, BelarusBelarus, , GeorgiaGeorgia, , KazakhstanKazakhstan, Kyrgyzstan, , Kyrgyzstan, MoldovaMoldova, , the Russian the Russian FederationFederation, Turkmenistan, Tajikistan, , Turkmenistan, Tajikistan, UkraineUkraine and and UzbekistanUzbekistan. . (EECAlink focuses on those underlined)(EECAlink focuses on those underlined)
• FP6:FP6: Armenia (3 - 250k€), Belarus (1 - 22k€),Armenia (3 - 250k€), Belarus (1 - 22k€),Ukraine (8 - 650k€), Russia (38 - €5.8Mio)Ukraine (8 - 650k€), Russia (38 - €5.8Mio)
• FP7:FP7: Armenia (8Armenia (8/2/25%/2/25%), Belarus (12), Belarus (12/2/17%/2/17%) ,) ,Georgia (10Georgia (10/4/40%/4/40%), Kazakhstan (9), Kazakhstan (9/2/22%/2/22%), Moldova ), Moldova (7(7/3/43%/3/43%), Russia (113), Russia (113/25/22%/25/22%),),
• Ukraine (28Ukraine (28/5/18%/5/18%), Uzbekistan (2), Uzbekistan (2/1/50%/1/50%))CPM Status March 2010CPM Status March 2010
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
13
5-ый конкурс «Здоровье»
• Бюджет: €650m
• Дата объявления: 30 July 2010
• Последняя дата внесения проектов :
FP7-HEALTH-2011-single-stage, deadline: 10 Nov. 2010 (tbc)
FP7-HEALTH-2011-two-stage, deadline: 13 Oct. 2010 (tbc)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
14
Некоторые данные по 7РП «Здоровье»
FP7 HEALTHFP7 HEALTH
Proposals received все страны- 21’829 , третьи страны 1464N° of participations 2315 591
Grant Agreements 405 123
(N° of participations 4241 327
EU funding €1’606 Mio
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
15
Приоритеты 5-ого конкурса
• Области главных приоритетовОбласти главных приоритетов::– the brain: neurodegenerative + lifestyle-
related aspects– diabetes/obesity & lifestyle-induced
conditions– antimicrobial drug resistance– emerging epidemics– health inequalities, …
• Исследовательские инициативы высокой Исследовательские инициативы высокой значимостизначимости::– Epigenomics – Better immunisation
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
16
Исследовательские инициативы Исследовательские инициативы
высокой значимостивысокой значимости• Major strategic investments to foster European
competitive position in target areas with important economical/societal return
• Programmatic approach (structuring the ERA): several research components integrated in each project, allowing synergies.
• High-impact outcomes expected from coherent & ambitious strategies
• Collaborative Project, but larger in size (€30 Mio)• Participation of SMEs (min. 15% of EU
contribution to each project)• Governance and management will be critical. • Adapted evaluation: single-stage, with hearings
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
17
Тематика клинических испытаний
Руководящие принципы:
• Двустадийная схема внесения
• Вклад EC : max. €6m/project in most cases
• Читсло партнеров: в каждом случае свое (with minimum 3)
• Продолжительность проектов: по усмотрению заявителей
• Поощряется участие больных
• Предусмотрены этические моменты (EU and national)
• Возможно участие субподрядчиков
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
18
Тематика клинических испытаний
Цель:
• Translating research into clinical practice
• Focus on investigator-driven CTs – relevant to public health
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
19
SME участие
Одна из задач: облегчить и увеличить участие SME
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
20
Принципы междуна-родного сотрудничества
• Болезни не имеют границ, поража-ют население богатых и бедных стран
• Здоровье является политическим приоритетом для большинства стран (богатых и бедных)
• Болезни богатых (рак, диабет, сер-дечно-сосудистые заболевания и др. ) поражают население развиваю-щихся стран и, наоборот (малярия, туберкулез,…).
• Лечение всегда универсально
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
21
• Все темы открыты для участников из третьих стран
• Некоторые темы имеют целевое значение
• Ряд тем получил название Specific International Cooperation Actions (так называемые SICAs)– Address specific issues that partner
countries face or have a global character, on the basis of mutual interest and benefit
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
22
Ключевые факторы успеха
– Предложения должны быть адресованы тематике, рабочей программе, конкретными не расплывчатыми; (not wishful thinking)
– Консорциум партнеров должен быть превосходным и соответствовать задачам (select the right partners)
– Предложения должны соответствовать всем требуемым критериям
– Должны быть убедительными для рецензента (don’t rely on reputation)
– Соответстовать основным правилам (deadlines, N° of participants, ceilings, length, ethics
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
23
• 3 критерия соответствия; • Пороги
Science & Technology excellence 3/5
Implementation & Management 3/5
Potential Impact 3/5
Overall 10/15
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
24
Европейское исследовательское пространство
(R&D aria)• 27 EU Member States27 EU Member States• +7 Outermost Regions+7 Outermost Regions• Guadeloupe, French Guiana, Martinique and Réunion (the
four French overseas departments), the Canaries (Spain), and the Azores and Madeira (Portugal)
• +12+12 Associated CountriesAssociated Countries(the EU neighbourhood countries)
• Albania, Bosnia and Herzegovina, Croatia, Iceland , Israel, Liechtenstein, FYR of Macedonia, Norway, Republic of Montenegro, Serbia, Switzerland, Turkey
• +FP7 Third Countries+FP7 Third Countries• Other countries worldwide Other countries worldwide
- can participate in FP7 - can participate in FP7 • - some can receive funding- some can receive funding (ICPC, incl. BRICS) and (ICPC, incl. BRICS) and
others only exceptionally others only exceptionally (high-income countries)(high-income countries)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
25
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
26
Участие третьих стран
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
27
• Участие Восточноевропейских стран (2007-2010)
• Russia: 35• Ukraine: 6• Georgia: 5• Rep.Moldova: 4• Belarus: 3• Armenia, Kazakhstan: 2• Uzbekistan: 1
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
28
Требования и финансирование
• Для большинства типов проектов Для большинства типов проектов (CP-IPs, (CP-IPs, small/medium CP-FPs):small/medium CP-FPs):
• Минимальное число участников: 3 из MS/AS• Средний объем: большой CP-IPs – €10.7 Mio /17 partners,
средний CP-FP - €3.5 Mio / 10 partners, малый CP-TP – €3.2 Mio / 8 partners
• Средний показатель участия третьих стран: 30% по грантам, 8% по участникам
• Specific International Cooperation ActionsSpecific International Cooperation Actions• Минимальное число участников: 2+2 (2 from MS/AS + 2
from ICPCs)• В среднем от третьих стран: 4 partners • Средний объем: CP-SICA - €3.4 Mio / 9 partners (5 MS/AS
+ 4 TC)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
29
Возможности 5-ого конкурса c точки
зрения сотрудничества • Programme-Level Cooperation with:
– Russia: 1.1-3 HTP Proteomics– Brazil: 1.1.4-5 Inflammatory and Autoimmune diseases– India: 2.2.1-4 Neurodegenerative paediatric diseases– India: 2.4.1-3 Cancer from Infectious Agents– Brazil: 3.4-3 Multilateral cooperation in Public Health
• Specific International Cooperation Actions: – 2.1.1-4 Pop. Genetics on Cardio-Metabolic Disorders– 2.3.3-2 Control of Dengue Fever– 2.4.3-4 Obesity and/or Diabetes in Specific Populations– 3.4-1 Reproductive Health and Health Equity
• Other topics of particular international nature: – 2.3.3-1 Zoonotic Viruses– 2.3.3-3 Major Epidemic Outbreaks– 2.3.1-2 Evolution/transfer of AMDR– 3.3-1 Determinants of Health– 3.4-2 Research Capacity
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
30
Где искать информацию?
• Calls for Proposals, Work Programme (Topics)http://cordis.europa.eu/fp7/health/
• National Contact Points (NCPs) - Information & support for applicants http://www.healthncpnet.eu
• FP6/FP7 projects databaseshttp://www.lifecompetence.eu/; http://www.healthcompetence.eu/
• Partner search toolshttp://www.smesgohealth.org/
• EU health research websitehttp://ec.europa.eu/research/health/
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
31
• Proposed topics for 2011 WP• • Activity 1 - Биотехнология, мето-
ды и технологии для медицины
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
32
Биотехнология, мето-ды и технологии
• 1.1 – High-throughput research• • 1.1-1 SME-targeted research for developing tools and
technologies for high-throughput research. • Funding scheme: collab. project, max €6m, 2-stage, one or more
proposals.
• 1.1-2 Genome-based biomarkers for patient stratification and pharmacogenomic strategies.
• Funding scheme: collab. project, max €6m, 2-stage, one or more proposals.
• 1.1-3 High-throughput proteomics for human health and disease. (Russia)
• Funding scheme: collab. project, max €3m, single-stage, one or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
33
Биотехнология, мето-ды и технологии
• 1.2 - Detection, diagnosis and monitoring
• • Closed in 2011
– 1.3 - Suitability, safety, efficacy of therapies
–– Closed in 2011
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
34
Биотехнология, мето-ды и технологии
• 1.4 Innovative therapeutic approaches and interventions
• 1.4-1 Regenerative medicine clinical trials. • Funding scheme: collab. project, max €6m, 2-stage, one or more
proposals.
• 1.4-2 Tools, technologies and devices for application in regenerative medicine.
• Funding scheme: collab. project, max €6m, 2-stage, one or more proposals.
• 1.4-3 Development and production of new, high-affinity protein scaffolds for therapeutic use.
• Funding scheme: collab. project, max €6m, 2-stage, one or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
35
Биотехнология, мето-ды и технологии
1.4 – Innovative therapeutic approaches and interventions
– 1.4-4 High impact project immunisation. – Funding scheme: collab. project, max €30m,
single-stage, max one proposal.
– 1.4-5 New therapeutic approaches in chronic inflammatory and autoimmune diseases. (Brazil)
– Funding scheme: collab. project, max €3m, single-stage, one or more proposals
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
36
• Proposed topics for 2011 WP
• Activity 2 - Сквозные исследова-ния в области здоровья (translating research for human health)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
37
Сквозные исследова-ния в области здоровья
• 2.1.1 – large-scale data-gathering:• 2.1.1-1 High impact initiative on the human epigenome. • Funding scheme: collab. project, max €30m, single-stage, max
one proposal.• 2.1.1-2 Proteins and their interactions in health and
disease. • Funding scheme: collab. project, max €12m, 2-stage, one or more
proposals.• 2.1.1-3 Large-scale genomics approaches to identify host
determinants of infectious diseases. • Funding scheme: collab. project, max €12m, single-stage, max
one proposal.• 2.1.1-4 Population genetic studies on cardio-metabolic
disorders in EU/AC and EECA populations. • Funding scheme: Specific International Cooperation Action (SICA),
collab. project, max €6m, single-stage, max one proposal.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
38
Сквозные исследова-ния в области здоровья
• 2.1 – Integrating biological data and processes
• 2.1.2 – Systems biology • Closed in 2011.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
39
Сквозные исследова-ния в области здоровья
• 2.2.1 – Research on the Brain and related diseases, human development and ageing:– 2.2.1-1 Investigator-driven clinical trials for
childhood-onset neurodegenerative diseases. – Funding scheme: collab. project, max €6m, 2-stage, one
or more proposals.– 2.2.1-2 Understanding the role of
neuroinflammation in neurodegenerative diseases.
– Funding scheme: collab. project, max €12m, 2-stage, one or more proposals.
– 2.2.1-3 Addictive and/or compulsive behaviour in children & adolescents: translating preclinical results into therapies
– Funding scheme: collab. project, max €6m, 2-stage, one or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
40
Сквозные исследова-ния в области здоровья
• 2.2.1 – Research on the Brain and related diseases, human development and ageing:– 2.2.1-4 Creating clinical and molecular tools for
experi-mental therapy of paediatric neurodegenerative disorders causing childhood dementia in Europe and India.
– Funding scheme: collab. project, max €3m, single-stage, one or more proposals.
– 2.2.1-5: ERA-Net on disease-related neuroscien-ces.
– Funding scheme: CA ERA-NET, ~€2m, single-stage, max. one proposal.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
41
Сквозные исследова-ния в области здоровья
• 2.2.2 – Human development and ageing: – 2.2.2-1 Investigator-driven clinical trials
for therapeutic interventions in elderly populations.
– Funding scheme: collab. project, max €6m, 2-stage, one or more proposals.
– 2.2.2-2 Linking human development and ageing.
– Funding scheme: collab. project, max €3m, 2-stage, one or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
42
Сквозные исследова-ния в области здоровья
• 2.3-1 Anti-microbial drug resistance
• 2.3.1-1 Investigator-driven clinical trials of off-patent antibiotics.
• Funding scheme: collab. project, max €6m, 2-stage, one or more proposals.
• 2.3.1-2 Multi-disciplinary research on the evolution and transfer of antibiotic resistance.
• Funding scheme: collab. project, max €12m, single-stage, max one proposal.
• 2.3.1-3 Management of Gram negative multi-drug resistant infections.
• Funding scheme: collab. project, max €12m, single-stage, max one proposal.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
43
Сквозные исследова-ния в области здоровья
• 2.3-1 Anti-microbial drug resistance
• 2.3.1-4 Development of multi-analyte diagnostic tests.
• Funding scheme: collab. project, max €3m, 2-stage, one or more proposals.
• 2.3.1-5 Development of tools to control microbial biofilms with relevance to clinical drug resistance.
• Funding scheme: collab. project, max €3m, 2-stage, one or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
44
Сквозные исследова-ния в области здоровья
• 2.3.2 – HIV/AIDS, malaria and tuberculosis
• Closed in 2011
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
45
Сквозные исследова-ния в области здоровья
• 2.3.3 – Potentially new and re-emerging epidemics• 2.3.3-1 Identification of factors promoting the emergence
of pathogens with human pandemic potential from pathogens with a zoonotic background and related prevention strategies.
• Funding scheme: collab. project, max €12m, two-stage, max one proposal.
• 2.3.3-2 Comprehensive control of Dengue fever under changing climatic conditions. (SICA: Latin Am. & Asia)
• Funding scheme: collab. project, max €6m, single-stage, one or more proposals.
• 2.3.3-3 Development of an evidence-based behavioural and communication package to respond to major epidemic outbreaks.
• Funding scheme: collab. project, max €2m, 2-stage, one or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
46
Сквозные исследова-ния в области здоровья
• 2.3.4 – Neglected infectious diseases
• Closed in 2011
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
47
Сквозные исследова-ния в области здоровья
• 2.4.1 – Cancer• 2.4.1-1 Investigator-driven, treatment trials for rare
cancers.• Funding scheme: collab. project, max €6m, 2-stage, one or
more proposals.
• 2.4.1-2 Translational research on cancers with poor prognosis
• Funding scheme: collab. project, max €3m, 2-stage, one or more proposals.
• 2.4.1-3 Epidemiology and aetiology of infection-related cancers (in Europe & India)
• Funding scheme: collab. project, max €3m, 1-stage, one or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
48
Сквозные исследова-ния в области здоровья
• 2.4.2 – Cardiovascular disease
– 2.4.2-1 Investigator-driven clinical trials for the management of cardiovascular diseases.
– Funding scheme: collab. project, max €12m, 2-stage, one or more proposals.
– 2.4.2-2 Evaluation and validation studies of clinically useful biomarkers in prevention and management of cardiovascular disease.
– Funding scheme: collab. project, max €6m, 2-stage, one or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
49
Сквозные исследова-ния в области здоровья
• 2.4.3 – Diabetes and obesity• 2.4.3-1 Investigator-driven clinical trials to reduce
diabetes complications. • Funding scheme: collab. project, max €6m, 2-stage, one or
more proposals.
• 2.4.3-2 Development of novel treatment strategies based on knowledge of cellular dysfunction.
• Funding scheme: collab. project, max €6m, 2-stage, one or more proposals.
• 2.4.3-3 Molecular and physiological effects of lifestyle factors on diabetes/obesity.
• Funding scheme: collab. project, max €6m, 2-stage, one or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
50
Сквозные исследова-ния в области здоровья
• 2.4.3 – Diabetes and obesity
• 2.4.3-4 Genetic and environmental factors in obesity and/or diabetes in specific populations.
• Funding scheme: SICA (Africa, Asia, Latin America, Mediterranean countries), max €3m, 2-stage, one or more proposals.
• 2.4.3-5 ERA-NET on diabetes prevention and treatment.
• Funding scheme: ERA-NET CA, ~€2m, single-stage, max one project.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
51
Сквозные исследова-ния в области здоровья
• 2.4.4 – Rare diseases• Closed in 2011
• 2.4.5 – Other chronic diseases• Closed in 2011
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
52
• Proposed topics for 2011 WP
• Activity 3 - Оптимизация ока-зания лечебной помощи- (Optimising the delivery of health care)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
53
Оптимизация ока-зания лечебной помощи
• 3.1 – Translating the results of clinical research outcome into clinical practice
• Closed in 2011
• 3.2 – Quality, efficiency and solidarity of healthcare systems
• Closed in 2011.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
54
Оптимизация ока-зания лечебной помощи
• 3.3 – Health promotion• 3.3-1 Developing methodologies to reduce inequities in the
determinants of health. • Funding scheme: collab. project, max €3m, 2-stage, one or more
proposals.• 3.3-2. Analysis of integrated strategies for sustainable
behaviour change. • Funding scheme: collab. project, max €3m, 2-stage, one or more
proposals.• 3.3-3 Developing and implementing methods for the
transfer of research into policy in the fields of health promotion and disease prevention.
• Funding scheme: collab. project, max €3m, single-stage, max one proposal.
• 3.3-4 A road-map for mental health research in Europe. • Funding scheme: CA, max €2m, single-stage, max one proposal.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
55
Оптимизация ока-зания лечебной помощи
• 3.4 – International public health & health systems• 3.4-1 Development and assessment of comprehensive and
integrated interventions and programmes to improve repro-ductive health and health equity.
• Funding scheme: SICA (all ICPC) collab. project, max €3m, single-stage, one or more proposals.
• 3.4-2 Building sustainable capacity for research for health and its social determinants in low and middle income countries.
• Funding scheme: CA, max €2m, single-stage, one or more proposals.
• 3.4-3 Multilateral cooperation between Europe, Africa and Latin America on public health and health services research.
• Funding scheme: CA, max €2m, single-stage, max one proposal.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
56
• Proposed topics for 2011 WP
• Activity 4 - Мероприятия поддержки и ответ на требования политики (support actions & response to policy need)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
57
Мероприятия поддержки
4.1 – Coordination and support actions across the theme• 4.1-1 Networking of major research institutions to
coordinate communication actions aimed at the media and the general public.
• Funding scheme: CA, max €2m, single-stage, max one proposal.• 4.1-2 Targeting publication bias. • Funding scheme: SA, max €0.5m, single-stage, one or more
proposals.• 4.1-3 Linking EU and Latin American policy-making
institutions in the field of health research.• Funding scheme: CA, max €2m, single-stage, max one proposal.• 4.1-4 Organisation of supporting actions and events
related to the presidency of the EU.• Funding scheme: SA, max €100,000, single-stage, one or more
proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
58
Мероприятия поддержки
• 4.2 – Responding to EU Policy needs– 4.2-1 Investigator-driven clinical trials on
off‑patent medicines for children. – Funding scheme: collab. project, max €6m,
single-stage, one or more proposals.– 4.2-2 Adverse drug reaction research. – Funding scheme: collab. project, max €3m,
single-stage, one or more proposals.– 4.2 3 New methodologies for clinical trials
in personalised medicine. – Funding scheme: collab. project, max €3m,
single-stage, one or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
59
ГНУ «Институт биофизики и клеточной инженерии НАН Беларуси»
Tel.: (+375 17) 284-17-49Fax: (+375 17) 284-23-59E-mail: [email protected]: http://www.ipb.org.by/ - войти в раздел « общая информация», а затем
– «НКТ»
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
60
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
61